KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

West Pharmaceutical Services (WST) EBITDA Margin (2016 - 2025)

West Pharmaceutical Services' EBITDA Margin history spans 17 years, with the latest figure at 19.45% for Q4 2025.

  • For Q4 2025, EBITDA Margin fell 186.0% year-over-year to 19.45%; the TTM value through Dec 2025 reached 19.03%, down 67.0%, while the annual FY2025 figure was 19.03%, 67.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 19.45% at West Pharmaceutical Services, down from 20.83% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 29.61% in Q2 2022 and bottomed at 15.33% in Q1 2025.
  • The 5-year median for EBITDA Margin is 21.83% (2023), against an average of 22.67%.
  • The largest annual shift saw EBITDA Margin skyrocketed 955bps in 2021 before it crashed -688bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 25.18% in 2021, then dropped by -27bps to 18.3% in 2022, then increased by 20bps to 21.98% in 2023, then decreased by -3bps to 21.31% in 2024, then decreased by -9bps to 19.45% in 2025.
  • Per Business Quant, the three most recent readings for WST's EBITDA Margin are 19.45% (Q4 2025), 20.83% (Q3 2025), and 20.05% (Q2 2025).